Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001140361-25-042491
Filing Date
2025-11-17
Accepted
2025-11-17 16:22:53
Documents
14
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10Q/A ef20059408_10qa.htm   iXBRL 10-Q/A 52466
5 EXHIBIT 31.1 ef20059408_ex31-1.htm EX-31.1 4049
6 EXHIBIT 31.2 ef20059408_ex31-2.htm EX-31.2 4114
  Complete submission text file 0001140361-25-042491.txt   215862

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA grce-20250930.xsd EX-101.SCH 3083
3 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE grce-20250930_lab.xml EX-101.LAB 27169
4 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE grce-20250930_pre.xml EX-101.PRE 14379
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20059408_10qa_htm.xml XML 4915
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-322-1602
Grace Therapeutics, Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 10-Q/A | Act: 34 | File No.: 001-35776 | Film No.: 251491328
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)